Hansruedi Loetscher
Overview
Explore the profile of Hansruedi Loetscher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1036
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruderisch N, Schlatter D, Kuglstatter A, Guba W, Huber S, Cusulin C, et al.
EBioMedicine
. 2017 Sep;
24:76-92.
PMID: 28923680
Therapeutic approaches to fight Alzheimer's disease include anti-Amyloidβ (Aβ) antibodies and secretase inhibitors. However, the blood-brain barrier (BBB) limits the brain exposure of biologics and the chemical space for small...
2.
Borroni E, Bohrmann B, Grueninger F, Prinssen E, Nave S, Loetscher H, et al.
J Pharmacol Exp Ther
. 2017 Jun;
362(3):413-423.
PMID: 28642233
Monoamine oxidase B (MAO-B) has been implicated in the pathogenesis of Alzheimer's disease (AD) and other neurodegenerative disorders. Increased MAO-B expression in astroglia has been observed adjacent to amyloid plaques...
3.
Villasenor R, Kuennecke B, Ozmen L, Ammann M, Kugler C, Gruninger F, et al.
J Cereb Blood Flow Metab
. 2017 Mar;
37(12):3683-3694.
PMID: 28273726
The blood-brain barrier (BBB) regulates differing needs of the various brain regions by controlling transport of blood-borne components from the neurovascular circulation into the brain parenchyma. The mechanisms underlying region-specific...
4.
Villasenor R, Ozmen L, Messaddeq N, Gruninger F, Loetscher H, Keller A, et al.
Sci Rep
. 2016 May;
6:25658.
PMID: 27149947
The Blood-Brain Barrier (BBB) restricts access of large molecules to the brain. The low endocytic activity of brain endothelial cells (BECs) is believed to limit delivery of immunoglobulins (IgG) to...
5.
Urich E, Schmucki R, Ruderisch N, Kitas E, Certa U, Jacobsen H, et al.
Sci Rep
. 2015 Sep;
5:14104.
PMID: 26411801
The blood-brain barrier and the blood-cerebrospinal fluid barrier prevent access of biotherapeutics to their targets in the central nervous system and therefore prohibit the effective treatment of neurological disorders. In...
6.
Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, et al.
Neuron
. 2014 Jan;
81(1):49-60.
PMID: 24411731
Although biotherapeutics have vast potential for treating brain disorders, their use has been limited due to low exposure across the blood-brain barrier (BBB). We report that by manipulating the binding...
7.
Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks D, et al.
Arch Neurol
. 2011 Oct;
69(2):198-207.
PMID: 21987394
Background: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD). Objectives: To investigate whether treatment with gantenerumab leads to a measurable...
8.
Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al.
J Alzheimers Dis
. 2011 Sep;
28(1):49-69.
PMID: 21955818
The amyloid-β lowering capacity of anti-Aβ antibodies has been demonstrated in transgenic models of Alzheimer's disease (AD) and in AD patients. While the mechanism of immunotherapeutic amyloid-β removal is controversial,...
9.
Metzger F, Sajid W, Saenger S, Staudenmaier C, van der Poel C, Sobottka B, et al.
J Biol Chem
. 2011 Apr;
286(22):19501-10.
PMID: 21460230
Insulin-like growth factor I (IGF-I) has important anabolic and homeostatic functions in tissues like skeletal muscle, and a decline in circulating levels is linked with catabolic conditions. Whereas IGF-I therapies...
10.
Lindemann L, Jacobsen H, Schuhbauer D, Knoflach F, Gatti S, Wettstein J, et al.
Eur J Pharmacol
. 2009 Nov;
628(1-3):6-10.
PMID: 19917275
Neuropsychiatric adverse events have been reported in influenza patients with and without exposure to oseltamivir (Tamiflu), triggering speculation as to whether oseltamivir may be interacting with any human receptors and...